$RMTG
Regenerative Medical Technology Group Inc.

2024 Q2 Form 10-Q Financial Statement

#000121390024045134 Filed on May 20, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $793.3K $817.0K
YoY Change 119.54% 3.92%
Cost Of Revenue $266.4K $248.0K
YoY Change 147.78% -0.54%
Gross Profit $526.9K $569.0K
YoY Change 107.58% 6.0%
Gross Profit Margin 66.41% 69.64%
Selling, General & Admin $657.9K $597.5K
YoY Change 4.96% 818420.55%
% of Gross Profit 124.86% 105.01%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $82.97K $76.57K
YoY Change 43.36% 35.22%
% of Gross Profit 15.75% 13.46%
Operating Expenses $740.9K $674.1K
YoY Change 8.21% 10.32%
Operating Profit -$214.0K -$105.1K
YoY Change -50.33% 41.63%
Interest Expense -$1.863M -$1.856M
YoY Change 16.46% 16.1%
% of Operating Profit
Other Income/Expense, Net $503.6K
YoY Change 0.0%
Pretax Income -$2.077M -$1.961M
YoY Change 2.29% 17.41%
Income Tax
% Of Pretax Income
Net Earnings -$2.077M -$1.961M
YoY Change 2.29% 17.41%
Net Earnings / Revenue -261.76% -240.02%
Basic Earnings Per Share -$0.17 -$0.16
Diluted Earnings Per Share -$0.17 -$0.16
COMMON SHARES
Basic Shares Outstanding 12.49M shares 12.49M shares
Diluted Shares Outstanding 12.49M shares 12.49M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $617.1K $579.4K
YoY Change -49.63% -64.6%
Cash & Equivalents $617.1K $579.4K
Short-Term Investments
Other Short-Term Assets $38.61K $45.50K
YoY Change
Inventory $6.680K
Prepaid Expenses $38.61K $45.50K
Receivables $24.19K $43.51K
Other Receivables $0.00 $0.00
Total Short-Term Assets $686.6K $668.4K
YoY Change -46.21% -61.58%
LONG-TERM ASSETS
Property, Plant & Equipment $360.3K $366.3K
YoY Change 175.61% 129.62%
Goodwill $1.680M $1.680M
YoY Change -71.06% -71.06%
Intangibles $207.8K $232.2K
YoY Change -31.95% -29.58%
Long-Term Investments
YoY Change
Other Assets $7.264K $7.264K
YoY Change 30.41% 30.41%
Total Long-Term Assets $2.364M $2.411M
YoY Change -62.28% -61.9%
TOTAL ASSETS
Total Short-Term Assets $686.6K $668.4K
Total Long-Term Assets $2.364M $2.411M
Total Assets $3.050M $3.079M
YoY Change -59.56% -61.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $562.2K $554.5K
YoY Change 66.88% 48.26%
Accrued Expenses $8.207M $7.364M
YoY Change 31.56% 35.59%
Deferred Revenue $372.9K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $17.27M $16.24M
YoY Change 143.47% 129.75%
Total Short-Term Liabilities $26.42M $24.36M
YoY Change 92.94% 88.42%
LONG-TERM LIABILITIES
Long-Term Debt $2.434M $2.430M
YoY Change -74.46% -72.36%
Other Long-Term Liabilities $32.07K $48.91K
YoY Change
Total Long-Term Liabilities $2.467M $2.479M
YoY Change -74.13% -71.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.42M $24.36M
Total Long-Term Liabilities $2.467M $2.479M
Total Liabilities $28.88M $26.84M
YoY Change 24.36% 23.56%
SHAREHOLDERS EQUITY
Retained Earnings -$66.03M -$63.95M
YoY Change 18.17% 18.77%
Common Stock $12.49K $12.49K
YoY Change 0.4% 0.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$25.83M -$23.76M
YoY Change
Total Liabilities & Shareholders Equity $3.050M $3.079M
YoY Change -59.56% -61.83%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$2.077M -$1.961M
YoY Change 2.29% 17.41%
Depreciation, Depletion And Amortization $82.97K $76.57K
YoY Change 43.36% 35.22%
Cash From Operating Activities $90.39K $108.0K
YoY Change -122.22% 1493.59%
INVESTING ACTIVITIES
Capital Expenditures $52.66K $59.15K
YoY Change 1015.68% 978.27%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$52.66K -$59.15K
YoY Change 1015.68% 978.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities 90.39K $108.0K
Cash From Investing Activities -52.66K -$59.15K
Cash From Financing Activities 0.000
Net Change In Cash 37.73K $48.81K
YoY Change -109.17% -670.17%
FREE CASH FLOW
Cash From Operating Activities $90.39K $108.0K
Capital Expenditures $52.66K $59.15K
Free Cash Flow $37.73K $48.81K
YoY Change -109.17% 3686.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33432
CY2024Q1 dei City Area Code
CityAreaCode
(800)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
889-9509
CY2024Q1 dei Security12b Title
Security12bTitle
None
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-56010
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
MESO NUMISMATICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0492191
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
433 Plaza Real Suite 275
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
CY2024Q1 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12493938 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
579352 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
530540 usd
CY2024Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
43506 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
23956 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
45500 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
20500 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
668358 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
574996 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
366270 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
359303 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7264 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5568 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
232159 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
256544 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
125004 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2714 usd
CY2024Q1 us-gaap Goodwill
Goodwill
1679978 usd
CY2023Q4 us-gaap Goodwill
Goodwill
1679978 usd
CY2024Q1 us-gaap Assets
Assets
3079033 usd
CY2023Q4 us-gaap Assets
Assets
2879103 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
554520 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
421334 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7363741 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6597422 usd
CY2024Q1 us-gaap Customer Advances Current
CustomerAdvancesCurrent
114880 usd
CY2023Q4 us-gaap Customer Advances Current
CustomerAdvancesCurrent
2000 usd
CY2024Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
3644 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2146 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
76092 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2714 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
16243808 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
15223519 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
24356687 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22249135 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48912 usd
CY2024Q1 mssv Convertible Notes Payable Net Of Discount
ConvertibleNotesPayableNetOfDiscount
37502 usd
CY2023Q4 mssv Convertible Notes Payable Net Of Discount
ConvertibleNotesPayableNetOfDiscount
35023 usd
CY2024Q1 mssv Notes Payable Net Of Discount
NotesPayableNetOfDiscount
2384656 usd
CY2023Q4 mssv Notes Payable Net Of Discount
NotesPayableNetOfDiscount
2382648 usd
CY2024Q1 us-gaap Liabilities
Liabilities
26835556 usd
CY2023Q4 us-gaap Liabilities
Liabilities
24674605 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12493938 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12493938 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12493938 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12493938 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
12494 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
12494 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40181074 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40181074 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63951151 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61990131 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-23756523 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-21795503 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3079033 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2879103 usd
CY2024Q1 us-gaap Revenues
Revenues
817034 usd
CY2023Q1 us-gaap Revenues
Revenues
786198 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
248043 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
249397 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
568991 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
536801 usd
CY2024Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
144283 usd
CY2023Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
141637 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
248382 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
209371 usd
CY2024Q1 mssv Officer Compensation
OfficerCompensation
22500 usd
CY2023Q1 mssv Officer Compensation
OfficerCompensation
22500 usd
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
76572 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
56628 usd
CY2024Q1 mssv Investor Relation
InvestorRelation
23268 usd
CY2023Q1 mssv Investor Relation
InvestorRelation
2250 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
159091 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
178626 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
674096 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
611012 usd
CY2024Q1 us-gaap Interest Expense Other
InterestExpenseOther
1854417 usd
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
1600426 usd
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1498 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1927 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2463 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1961020 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1670247 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12493938 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12443938 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-21795503 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1961020 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-23756523 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11982292 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1670247 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-13652939 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1961020 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1670247 usd
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1024778 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
765963 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
76572 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
56628 usd
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1498 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1927 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2463 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
19550 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
52995 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
25000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1696 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1012384 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
911816 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
107966 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6775 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59154 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5486 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59154 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5486 usd
CY2023Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
9850 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-9850 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
48812 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8561 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
530540 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1645185 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
579352 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1636624 usd
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On July 2, 2018, the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of the Company’s issued and outstanding shares of common stock held by the holders of record. The prior year financials have been changed to reflect the 1-for-1,000 reverse stock split.
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates in Financial Statement Presentation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates included in these financial statements are associated with accounting for the goodwill, derivative liability, valuation of preferred stock, and for the valuation of assets and liabilities in business combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassifications</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications.</p>
CY2024Q1 us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
250000 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
0 usd
CY2020Q4 mssv Cashless Warrants Purchased
CashlessWarrantsPurchased
15000000 shares
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2479 usd
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
116679786 shares
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
126884881 shares
CY2024Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
3644 usd
CY2024Q1 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
3644 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2146 usd
CY2023Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
2146 usd
CY2023 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7679 usd
CY2024Q1 mssv Outstanding Convertible Notes
OutstandingConvertibleNotes
0 usd
CY2023 mssv Outstanding Convertible Notes
OutstandingConvertibleNotes
9850 usd
CY2019Q4 us-gaap Long Term Debt Term
LongTermDebtTerm
P4Y
CY2019Q4 mssv Promissory Note Premium Interest
PromissoryNotePremiumInterest
0.20 pure
CY2020Q4 mssv Penalty
Penalty
5379624 usd
CY2020Q4 mssv Aggregate Principal Amount
AggregatePrincipalAmount
5379624 usd
CY2020Q4 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.15 pure
CY2024Q1 mssv Going Concern
GoingConcern
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Going Concern</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of $63,951,151 and a working capital deficit of $23,688,329 as of March 31, 2024 and future losses are anticipated. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ability of the Company to continue its operations as a going concern is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will require additional funding to finance the growth of its current and expected future operations as well to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63951151 usd
CY2024Q1 mssv Working Capital Deficit
WorkingCapitalDeficit
23688329 usd
CY2024Q1 us-gaap Revenues
Revenues
817034 usd
CY2023Q1 us-gaap Revenues
Revenues
786198 usd
CY2024Q1 us-gaap Revenues
Revenues
817034 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
248043 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
568991 usd
CY2024Q1 mssv Percentage Of Gross Profit
PercentageOfGrossProfit
0.6964 pure
CY2024Q1 us-gaap Assets
Assets
3079033 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1961020 usd
CY2019Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.2
CY2019Q4 mssv Aggregate Exchange Amount
AggregateExchangeAmount
97252 usd
CY2024Q1 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
0 usd
CY2023 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
9850 usd
CY2020 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
262376 usd
CY2023Q4 mssv Secured Note Exchange
SecuredNoteExchange
2506827 usd
CY2023Q4 mssv Aggregate Consideration
AggregateConsideration
300000 usd
CY2023Q4 mssv Aggregate Principal Amount
AggregatePrincipalAmount
1999999 usd
CY2023Q4 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.06 pure
CY2024Q1 us-gaap Principal Amount Outstanding Of Loans Held In Portfolio
PrincipalAmountOutstandingOfLoansHeldInPortfolio
1999999 usd
CY2023Q4 us-gaap Principal Amount Outstanding Of Loans Held In Portfolio
PrincipalAmountOutstandingOfLoansHeldInPortfolio
1999999 usd
CY2020Q4 mssv Promissory Bebentures Lender Amount
PromissoryBebenturesLenderAmount
110000 usd
CY2020Q4 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.15 pure
CY2020Q4 us-gaap Long Term Debt Term
LongTermDebtTerm
P2Y
CY2020Q4 mssv Cashless Warrants Purchased
CashlessWarrantsPurchased
1000000 shares
CY2020Q4 mssv Advance From Lender
AdvanceFromLender
100000 usd
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
10000 usd
CY2020Q4 mssv Warrants Issued
WarrantsIssued
1000000 shares
CY2021Q1 mssv Promissory Bebentures Lender Amount
PromissoryBebenturesLenderAmount
1000000 usd
CY2021Q1 mssv Annual Interest Rate
AnnualInterestRate
0.15 pure
CY2021Q1 us-gaap Long Term Debt Term
LongTermDebtTerm
P1Y
CY2021Q1 mssv Cashless Warrants Purchased
CashlessWarrantsPurchased
10000000 shares
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.03
CY2021Q1 mssv Advance From Lender
AdvanceFromLender
900000 usd
CY2021Q1 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
100000 usd
CY2024Q1 mssv Warrants Issued
WarrantsIssued
10000000 shares
CY2024Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
237811 usd
CY2021Q2 mssv Promissory Bebentures Lender Amount
PromissoryBebenturesLenderAmount
11600000 usd
CY2021Q2 mssv Annual Interest Rate
AnnualInterestRate
0.12 pure
CY2021Q2 us-gaap Long Term Debt Term
LongTermDebtTerm
P3Y
CY2021Q2 mssv Cashless Warrants Purchased
CashlessWarrantsPurchased
70000000 shares
CY2021Q2 mssv Advance From Lender
AdvanceFromLender
10500000 usd
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
1100000 usd
CY2021Q2 mssv Warrants Issued
WarrantsIssued
70000000 shares
CY2021Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
5465726 usd
CY2021Q3 us-gaap Loans And Leases Receivable Gross Carrying Amount
LoansAndLeasesReceivableGrossCarryingAmount
20991 usd
CY2021Q3 mssv Interest Rate
InterestRate
0.0899 pure
CY2021Q3 mssv Interest Monthly Payments
InterestMonthlyPayments
504.94 usd
CY2021Q3 mssv Promissory Bebentures Lender Amount
PromissoryBebenturesLenderAmount
1100000 usd
CY2021Q3 mssv Annual Interest Rate
AnnualInterestRate
0.12 pure
CY2021Q3 us-gaap Long Term Debt Term
LongTermDebtTerm
P3Y
CY2021Q3 mssv Cashless Warrants Purchased
CashlessWarrantsPurchased
7500000 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.085
CY2021Q3 mssv Advance From Lender
AdvanceFromLender
1000000 usd
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
100000 usd
CY2021Q3 mssv Warrants Issued
WarrantsIssued
7500000 shares
CY2021Q3 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
360607 usd
CY2024Q1 mssv Outstanding Loan
OutstandingLoan
7958 usd
CY2023 mssv Outstanding Loan
OutstandingLoan
7958 usd
CY2024Q1 mssv Participating Mortgage Loan Unamortized Debt Discount Amount
ParticipatingMortgageLoanUnamortizedDebtDiscountAmount
0 usd
CY2023Q4 mssv Participating Mortgage Loan Unamortized Debt Discount Amount
ParticipatingMortgageLoanUnamortizedDebtDiscountAmount
0 usd
CY2021Q4 mssv Promissory Bebentures Lender Amount
PromissoryBebenturesLenderAmount
84000 usd
CY2021Q4 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
22162 usd
CY2021Q4 mssv Premium Percent
PremiumPercent
0.05 pure
CY2021Q4 us-gaap Premiums Earned Net Life
PremiumsEarnedNetLife
111470 usd
CY2021Q4 mssv Debt Instrument Bears Interest Rate
DebtInstrumentBearsInterestRate
0.12 pure
CY2021Q4 us-gaap Long Term Debt Term
LongTermDebtTerm
P17M
CY2024Q1 mssv Promissory Notes Payable
PromissoryNotesPayable
19722931 usd
CY2023Q4 mssv Promissory Notes Payable
PromissoryNotesPayable
19722931 usd
CY2024Q1 us-gaap Other Deferred Costs Gross
OtherDeferredCostsGross
7800 usd
CY2023Q4 us-gaap Other Deferred Costs Gross
OtherDeferredCostsGross
7800 usd
CY2024Q1 mssv Promissory Notes Payable Discount
PromissoryNotesPayableDiscount
1086979 usd
CY2023Q4 mssv Promissory Notes Payable Discount
PromissoryNotesPayableDiscount
2100966 usd
CY2024Q1 us-gaap Other Deferred Costs Net
OtherDeferredCostsNet
7487 usd
CY2023Q4 us-gaap Other Deferred Costs Net
OtherDeferredCostsNet
15798 usd
CY2024Q1 us-gaap Notes Payable
NotesPayable
18636265 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
17613966 usd
CY2024Q1 mssv Aggregate Consideration
AggregateConsideration
0 usd
CY2024Q1 mssv Secured Note Exchange
SecuredNoteExchange
766319 usd
CY2024Q1 us-gaap Interest Expense Savings Deposits
InterestExpenseSavingsDeposits
1022299 usd
CY2023 us-gaap Interest Expense Savings Deposits
InterestExpenseSavingsDeposits
3049999 usd
CY2024Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1511297 usd
CY2024Q1 mssv Outstanding Promissory Notes Payable
OutstandingPromissoryNotesPayable
19730731 usd
CY2023Q4 mssv Outstanding Promissory Notes Payable
OutstandingPromissoryNotesPayable
19730731 usd
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
88878 shares
CY2024Q1 us-gaap Share Price
SharePrice
0.041
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.06
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0496 pure
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y9M
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.01 pure
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
6944 usd
CY2023 mssv Gain Loss On Derivative Fair Value Instruments
GainLossOnDerivativeFairValueInstruments
3450 usd
CY2023 mssv Derivative Instruments Conversions
DerivativeInstrumentsConversions
1348 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
2146 usd
CY2024Q1 mssv Gain Loss On Derivative Fair Value Instruments
GainLossOnDerivativeFairValueInstruments
-1498 usd
CY2024Q1 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
3644 usd
CY2020 mssv Issuance Of Warrants
IssuanceOfWarrants
16000000 shares
CY2021Q1 mssv Warrants Issued For Debt
WarrantsIssuedForDebt
237811 usd
CY2021Q2 mssv Warrants Issued For Debt
WarrantsIssuedForDebt
5465726 usd
CY2021Q3 mssv Issuance Of Warrants
IssuanceOfWarrants
7500000 shares
CY2021Q3 mssv Warrants Issued For Debt
WarrantsIssuedForDebt
360607 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
103500000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.082
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
16000000 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.03
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
87500000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.091
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
10000000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.033
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
77500000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.099
CY2024Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1000 shares
CY2024Q1 us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
0.8
CY2022Q1 mssv Monthly Based On Annual Rate
MonthlyBasedOnAnnualRate
90000 usd
CY2024Q1 us-gaap Other Expenses
OtherExpenses
503552 usd
CY2022Q1 mssv Monthly Based On Annual Rate
MonthlyBasedOnAnnualRate
90000 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
896 shares
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
448 shares
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
448 shares
CY2023Q1 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
101158 usd
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Assets
EffectiveIncomeTaxRateReconciliationDispositionOfAssets
0.275 pure
CY2024Q1 us-gaap Area Of Land
AreaOfLand
1647 sqm
CY2024Q1 mssv Monthly Rent
MonthlyRent
2714 usd
CY2024Q1 us-gaap Security Deposit
SecurityDeposit
5588 usd
CY2024Q1 us-gaap Payments For Rent
PaymentsForRent
15028 usd
CY2023Q1 us-gaap Payments For Rent
PaymentsForRent
11062 usd
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12443938 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12493938 shares
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
167852 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
166774 usd
CY2024Q1 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
559302 usd
CY2023Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
501226 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
360884 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
308697 usd
CY2024Q1 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
366270 usd
CY2023Q4 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
359303 usd
CY2024Q1 us-gaap Depreciation
Depreciation
52187 usd
CY2023Q1 us-gaap Depreciation
Depreciation
32243 usd
CY2024Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
487700 usd
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
487700 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
255541 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
231156 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
232159 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
256544 usd
CY2024Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2024Q1 mssv Amortization Expense Intellectual Property
AmortizationExpenseIntellectualProperty
24385 usd
CY2023Q1 mssv Amortization Expense Intellectual Property
AmortizationExpenseIntellectualProperty
24385 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2024Q1 mssv Monthly Rent
MonthlyRent
2714 usd
CY2024Q1 us-gaap Security Deposit Liability
SecurityDepositLiability
5588 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
57069 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
76092 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
133161 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
8157 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
125004 usd
CY2021Q3 mssv Stock Purchase Percentage
StockPurchasePercentage
1 pure
CY2021Q3 us-gaap Cash
Cash
225000 usd
CY2024Q1 mssv Purchase Price
PurchasePrice
6229000 usd
CY2024Q1 us-gaap Cash
Cash
175000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
5805438 usd
CY2023 us-gaap Goodwill Impairment Loss Net Of Tax
GoodwillImpairmentLossNetOfTax
4125460 usd
CY2023Q4 us-gaap Goodwill
Goodwill
1679978 usd
CY2024Q1 us-gaap Goodwill Impairment Loss Net Of Tax
GoodwillImpairmentLossNetOfTax
4125460 usd
CY2024Q1 us-gaap Goodwill
Goodwill
1679978 usd
CY2024Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4125460 usd
CY2024Q1 us-gaap Goodwill
Goodwill
1679978 usd
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
usd
CY2024Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023 us-gaap Servicing Asset At Fair Value Additions
ServicingAssetAtFairValueAdditions
usd
CY2024Q1 us-gaap Servicing Asset At Fair Value Additions
ServicingAssetAtFairValueAdditions
usd
CY2024Q1 mssv Derivative Instruments Conversions
DerivativeInstrumentsConversions
usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2023 mssv Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
shares
CY2023 mssv Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2024Q1 mssv Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
shares
CY2024Q1 mssv Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
usd
CY2023 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
usd
CY2024Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
usd
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001760026

Files In Submission

Name View Source Status
0001213900-24-045134-index-headers.html Edgar Link pending
0001213900-24-045134-index.html Edgar Link pending
0001213900-24-045134.txt Edgar Link pending
0001213900-24-045134-xbrl.zip Edgar Link pending
ea0206530-10q_meso.htm Edgar Link pending
ea020653001ex3-1_meso.htm Edgar Link pending
ea020653001ex31-1_meso.htm Edgar Link pending
ea020653001ex31-2_meso.htm Edgar Link pending
ea020653001ex32-1_meso.htm Edgar Link pending
ex3-1_001.jpg Edgar Link pending
ex3-1_002.jpg Edgar Link pending
ex3-1_003.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mssv-20240331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mssv-20240331_cal.xml Edgar Link unprocessable
mssv-20240331_lab.xml Edgar Link unprocessable
mssv-20240331_def.xml Edgar Link unprocessable
mssv-20240331_pre.xml Edgar Link unprocessable
ea0206530-10q_meso_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending